

USES: Megaloblastic or macrocytic anemia caused by folic acid deficiency, overdose of folic acid antagonist, methotrexate/pyrimethamine/trimetrexate/trimethoprim toxicity, pneumocystosis, toxoplasmosis

CONTRAINDICATIONS: Hypersensitivity to this product or folic acid, benzyl alcohol; anemias other than megaloblastic not associated with vit B₁₂ deficiency

DOSAGE AND ROUTES

Methotrexate toxicity/leucovorin rescue

• **Adult/child:** PO/IM/IV normal elimination given 6 hr after dose of methotrexate (10 mg/m²) until methotrexate <5 × 10⁻⁸ m, CCR >50% above prior level, or methotrexate level 5 × 10⁻⁸ m at 24 hr or >9 × 10⁻⁸ m at 48 hr; give leucovorin 100 mg/m² q3hr until level drops to <10⁻⁸ m

Megaloblastic anemia caused by enzyme deficiency

• **Adult/child:** PO/IV/IM up to 6 mg/day
Pyrimethamine/trimethoprim toxicity prevention

• **Adult/child:** PO/IV 5-15 mg/day

Advanced colorectal cancer

• **Adult:** IV 200 mg/m², then 5-FU 370 mg/m² or leucovorin 20 mg/m², then 5-FU 425 mg/m²; give daily × 5 days q4-5wk

HIGH ALERT

leuprolide (Rx)

(loo-proe'lide)

Eligard, Lupron Depot, Lupron Depot-Ped, Lupron 

Func. class.: Antineoplastic hormone

Chem. class.: Gonadotropin-releasing hormone

ACTION: Causes initial increase in circulating levels of LH, FSH; continuous administration results in decreased LH, FSH; in men, testosterone is reduced to castrate levels; in premenopausal

women, estrogen is reduced to menopausal levels

USES: Metastatic prostate cancer (inj implant), management of endometriosis, central precocious puberty, uterine leiomyomata (fibroids)

Unlabeled uses: Breast cancer, recurrent priapism, benign prostatic hyperplasia

CONTRAINDICATIONS: Pregnancy, breastfeeding, hypersensitivity to GnRH or analogs, thromboembolic disorders, undiagnosed vaginal bleeding; Eligard should not be used in women, children

Precautions: Edema, hepatic disease, CVA, MI, seizures, hypertension, diabetes mellitus, HF, depression, osteoporosis, spinal cord compression, urinary tract obstruction

DOSAGE AND ROUTES

Advanced prostate cancer

• **Adult:** SUBCUT 1 mg/day; IM 7.5 mg/depot dose monthly; IM 22.5 mg depot q3mo; or IM 30 mg depot q4mo; or IM 45 mg depot q6mo; SUBCUT (Eligard) 7.5 mg q mo; SUBCUT 22.5 mg (Eligard) q 3 mo; SUBCUT 45 mg (Eligard) q mo

Endometriosis

• **Adult:** IM 3.75 mg depot monthly for 6 mo or 11.25 mg q3mo for 6 mo or 30 mg q4mo

Anemia related to uterine fibroids

• **Adult:** IM 3.75 mg depot q mo × 3 mo or 11.25 mg depot as a single dose

Central precocious puberty

• **Child:** SUBCUT 50 mcg/kg/day; may increase by 10 mcg/kg/day as needed

• **Child >37.5 kg:** IM Lepron Depot-Ped 15 mg q4wk

• **Child 25-37.5 kg:** IM Lepron Depot-Ped 11.25 mg q4wk

• **Child ≤25 kg:** IM Lepron Depot-Ped 7.5 mg q4wk

Benign prostatic hyperplasia (BPH) (unlabeled)

• **Adult:** SUBCUT (sol for inj) 1 mg/day, IM (injection susp) 3.75 mg q28day × 24 wk

Available forms: Lupron Depot inj: 3.75, 7.5, 11.25, 15, 22.5, 30, 45 mg;